Aclarion

ACON

Market cap $3.27M

Broomfield, CO, February 5, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

Company anticipates no capital raises prior to expected value enhancing catalysts  Cash runway into 2028 ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of its 2026 Shareholder Letter from the Chairman.

Broomfield, CO, February 03, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established an agreement with Source Healthcare, a state-of-the-art orthopedic and regenerative health clinic in Los Angeles to help address a key gap in addressing low back pain.

Expands availability of Nociscan in the greater Los Angeles area Reinforces Nociscan's non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedure Supports scalable growth strategy while building data assets critical to payer and provider adoption BROOMFIELD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established an agreement with Source Healthcare, a state-of-the-art orthopedic and regenerative health clinic in Los Angeles to help address a key gap in addressing low back pain.

Debt-Free Balance Sheet With $21.6 Million in Cash BROOMFIELD, Colo., Jan. 13, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

BROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of a $10.4 million common-stock-only financing at $5.18 per share in a clean capital raise structure.

BROOMFIELD, Colo., January 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025 Annual Nociscan scan volumes increased 69% year-over-year in 2025 Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, extending cash runway into 2027 and providing strategic flexibility for continued commercial growth Company aims to enroll approximately 25% of patients in CLARITY trial by the end of Q2 2026, with the first internal readout on interim data anticipated in Q3 2026 BROOMFIELD, Colo., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain today provided a comprehensive corporate update, including financial results and strategic progress as the Company enters 2026 advancing its proprietary Nociscan platform.

BROOMFIELD, Colo., Jan. 06, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) –  Aclarion, Inc.

Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational requirements to screen and enroll patients in CLARITY First readout on interim data expected after initial cohort of patients achieves 3-month follow up visit in 3Q 2026 BROOMFIELD, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that Northwestern Medicine and Scripps Health have enrolled their first patients in the company's pivotal CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial, advancing enrollment progress in the trial.